ライフサイエンスコーパス: invasive aspergillosis

1 hesized that 12/15-LOX is also active during invasive aspergillosis.

2 5-LOX (Alox15) are profoundly susceptible to invasive aspergillosis.

3 iconazole treatment failure in patients with invasive aspergillosis.

4 ogression and mortality in a murine model of invasive aspergillosis.

5 roup criteria classified these as "probable" invasive aspergillosis.

6 es in immunocompromised patients who develop invasive aspergillosis.

7 from those of the more commonly encountered invasive aspergillosis.

8 ssue-invasive hyphae, disseminate, and cause invasive aspergillosis.

9 ing as a causative agent of life-threatening invasive aspergillosis.

10 causal agent of the life-threatening disease invasive aspergillosis.

11 ctin inhibits excessive lung inflammation in invasive aspergillosis.

12 demonstrating improved outcomes of treating invasive aspergillosis.

13 osphamide-treated BALB/c mice with cutaneous invasive aspergillosis.

14 gliotoxin contributes to pathogenesis during invasive aspergillosis.

15 n synthesis and are used clinically to treat invasive aspergillosis.

16 or amphotericin B formulation as therapy for invasive aspergillosis.

17 corticosteroid-immunosuppressed mice against invasive aspergillosis.

18 iconazole has become the agent of choice for invasive aspergillosis.

19 apy is increasingly used in the treatment of invasive aspergillosis.

20 y available nonculture method for diagnosing invasive aspergillosis.

21 detection of invasive Candida infection and invasive aspergillosis.

22 diagnostic and therapeutic interventions in invasive aspergillosis.

23 ly deficit in CCR4 (CCR4-/-) did not develop invasive aspergillosis.

24 system, leading to the false presumption of invasive aspergillosis.

25 pergillus fumigatus, the leading etiology of invasive aspergillosis.

26 rulence of the wild type in a mouse model of invasive aspergillosis.

27 ature of the echinocandins, particularly for invasive aspergillosis.

28 1/CCL2 in the lungs of neutropenic mice with invasive aspergillosis.

29 posed them to doxycycline after the onset of invasive aspergillosis.

30 vising future therapeutic strategies against invasive aspergillosis.

31 tin-deficient mice in a neutropenic model of invasive aspergillosis.

32 ere the most common radiographic findings in invasive aspergillosis.

33 portant role in normal host defenses against invasive aspergillosis.

34 ms were associated with significant risk for invasive aspergillosis.

35 toxocariasis, congenital toxoplasmosis, and invasive aspergillosis.

36 tenuate fungal virulence in a mouse model of invasive aspergillosis.

37 ) increased the odds of early posttransplant invasive aspergillosis.

38 e different for invasive candidiasis and for invasive aspergillosis.

39 reduction in mortality in a murine model of invasive aspergillosis.

40 act the sensitivity of mcfDNA sequencing for invasive aspergillosis.

41 killing and, in turn, host susceptibility to invasive aspergillosis.

42 ation because of concerns for posttransplant invasive aspergillosis.

43 rtality up until day 42 in participants with invasive aspergillosis.

44 mbination therapy with azole monotherapy for invasive aspergillosis.

45 test that support the diagnosis of probable invasive aspergillosis.

46 g conditions, which overlap risk factors for invasive aspergillosis.

47 e developments in the molecular diagnosis of invasive aspergillosis.

48 rapy for invasive fungal infections, such as invasive aspergillosis.

49 ended as primary treatment for patients with invasive aspergillosis.

50 to voriconazole for the primary treatment of invasive aspergillosis.

51 12 weeks or less in the primary treatment of invasive aspergillosis.

52 and evaluated different case definitions of invasive aspergillosis.

53 ehold as potential source of azole-resistant invasive aspergillosis.

54 ecisions in patients with triazole-resistant invasive aspergillosis.

55 ungal burden in a neutropenic mouse model of invasive aspergillosis.

56 ce of EAPCRI protocols in an animal model of invasive aspergillosis.

57 of protective innate immune responses during invasive aspergillosis.

58 r donors for PTX3 SNPs modifying the risk of invasive aspergillosis.

59 and evaluated different case definitions of invasive aspergillosis.

60 protects CGD mice from colitis and also from invasive aspergillosis.

61 antly reduced virulence in a murine model of invasive aspergillosis.

62 rum GM quantification for early detection of invasive aspergillosis.

63 ith an increase in the 3-year probability of invasive aspergillosis (12% vs. 1%, P=0.02) and death th

64 fungal infections (36% vs. 7%, P=0.0007) and invasive aspergillosis (14% vs. 2%, P=0.02) was signific

65 ccesses by type of IFI included 7 of 12 with invasive aspergillosis, 2 of 2 with invasive fusariosis,

66 15), Pseudomonas aeruginosa (27%, 4 of 15), invasive aspergillosis (20%, 3 of 15), and Enterobacter

67 Of these, 158 had invasive aspergillosis, 44 were colonized, and 12 had co

68 illus fumigatus) is the most common cause of invasive aspergillosis, a frequently fatal lung disease

69 Aspergillus fumigatus causes invasive aspergillosis, a potentially fatal infection in

70 It has previously been reported that invasive aspergillosis, a prototypic opportunistic infec

71 be licensed was caspofungin, for refractory invasive aspergillosis (about 40% response rate) and the

72 haplotypes (S3 and S4) increased the risk of invasive aspergillosis (adjusted hazard ratio for S3, 2.

73 onor haplotype S4 also increased the risk of invasive aspergillosis (adjusted odds ratio, 2.49; 95% C

74 ifungal immunity result in increased risk of invasive aspergillosis after chemotherapy or transplanta

75 orphisms were shown to influence the risk of invasive aspergillosis among hematopoietic stem cell tra

76 of TLR polymorphisms in conferring a risk of invasive aspergillosis among recipients of allogeneic he

77 the donor TLR4 haplotype S4 and the risk of invasive aspergillosis among recipients of hematopoietic

78 ulticenter study involving 107 patients with invasive aspergillosis and 223 matched controls.

79 tudy patients had fungal pneumonitis; 4% had invasive aspergillosis and 3% had cryptococcosis.

80 invasive fungal disease (IFD), particularly invasive aspergillosis and candidiasis.

81 deficiency type I confer a predisposition to invasive aspergillosis and candidiasis.

82 s a critical early host defense mechanism in invasive aspergillosis and demonstrate NK cells to be an

83 tigated the role of TLR9 in murine models of invasive aspergillosis and fungal asthma.

84 ting may be useful for the diagnosis of both invasive aspergillosis and invasive candidiasis, when in

85 ine dilution into account, reliably detected invasive aspergillosis and may be a promising diagnostic

86 r mold-active triazoles for the treatment of invasive aspergillosis and mucormycosis after solid orga

87 Patients diagnosed with invasive aspergillosis and mucormycosis using plasma cel

88 It is approved for the treatment of invasive aspergillosis and mucormycosis.

89 Invasive aspergillosis and other fungal infections occur

90 escribe the case of a patient with improving invasive aspergillosis and paradoxically rising serum ga

91 Furthermore, nosocomial infections such as invasive aspergillosis and Pseudomonas aeruginosa occurr

92 Enterobacter bacteremia, invasive aspergillosis, and disseminated Candida infecti

93 fungal infections, invasive mold infections, invasive aspergillosis, and invasive candidiasis during

94 tional amphotericin B as primary therapy for invasive aspergillosis, and is the new standard of care

95 as performed, radiology data consistent with invasive aspergillosis, and the timing of initiation of

96 early IFN-gamma in the lungs in neutropenic invasive aspergillosis, and this is an important mechani

97 to be effective in reducing the incidence of invasive Aspergillosis as compared with no prophylaxis.

98 We developed invasive aspergillosis (Aspergillus fumigatus) and mucor

99 were free of IFD, invasive candidiasis, and invasive aspergillosis at 1 year.

100 is considered a significant risk factor for invasive aspergillosis but is almost always associated w

101 action may facilitate the early diagnosis of invasive aspergillosis, but have limitations.

102 NK cells mediate their protective effect in invasive aspergillosis by acting as the major source of

103 above the threshold considered positive for invasive aspergillosis by the recently licensed double s

104 addition to its emergence in the therapy of invasive aspergillosis by triazole medicines, it has bee

105 The diagnosis of invasive aspergillosis can be challenging in cancer pati

106 Invasive aspergillosis carries a high mortality with a r

107 rate variability in the numbers of diagnosed invasive aspergillosis cases in oncology centers, and a

108 A recent report on several cases of invasive aspergillosis caused by Neosartorya udagawae su

109 Invasive aspergillosis caused by triazole-resistant stra

110 Invasive aspergillosis causes significant mortality amon

111 using multiple pulmonary diseases, including invasive aspergillosis, chronic necrotizing aspergillosi

112 festations of Aspergillus infections include invasive aspergillosis, chronic pulmonary aspergillosis

113 ransplant recipients with proven or probable invasive aspergillosis collected as part of the Transpla

114 tive azoles against 731 AFM isolates causing invasive aspergillosis collected in Europe (EU; n = 449)

115 Development of invasive aspergillosis correlates with impairments in in

116 CMC, invasive candidiasis, invasive aspergillosis, deep dermatophytosis, pneumocyst

117 Finally, in the context of neutropenic invasive aspergillosis, depletion of DCs resulted in imp

118 Invasive aspergillosis develops in immunocompromised pat

119 Eight patients presented with invasive aspergillosis due to TR46/Y121F/T289A, and trea

120 Secondary outcomes were invasive aspergillosis, empirical antifungal therapy, an

121 embolism, pneumonia, secondary peritonitis, invasive aspergillosis, endocarditis and myocardial infa

122 , A. fumigatus is the most frequent agent of invasive aspergillosis, followed by A. lentulus and A. v

123 ients with a potentially low pretest risk of invasive aspergillosis following effective antimold prop

124 has been used as an aid in the diagnosis of invasive aspergillosis for almost 2 decades.

125 d comparison clinical trial for treatment of invasive aspergillosis found that the efficacy of isavuc

126 infections is still limited, mouse models of invasive aspergillosis fulfill a critical void for study

127 poorly defined in patients with GM-positive invasive aspergillosis (GPA).

128 ared them with contemporaneous patients with invasive aspergillosis (group B; n = 54) and with matche

129 cy of the echinocandins for the treatment of invasive aspergillosis has been based on historically co

130 Management of invasive aspergillosis has been improved by biomarker as

131 Invasive aspergillosis has emerged as an important cause

132 Because outbreaks of invasive aspergillosis have been linked to hospital cons

133 branching hyphae, suggesting a diagnosis of invasive aspergillosis; however, occasional yeast-like c

134 Patients with invasive aspergillosis (IA) (3/3) had positive GM at bas

135 To investigate risk factors for invasive aspergillosis (IA) after kidney transplantation

136 unit (ICU) patients with probable or proven invasive aspergillosis (IA) and 100 ICU patients without

137 l study, 211 samples from 10 proven/probable invasive aspergillosis (IA) and 2 possible IA cases and

138 entified 93 patients with proven or probable invasive aspergillosis (IA) and GM values of >or=0.50 fr

139 between clinical cases from colonization of invasive aspergillosis (IA) and major building construct

140 Outbreaks of invasive aspergillosis (IA) are believed to be caused by

141 iral therapy (cART), roughly 50% of cases of invasive aspergillosis (IA) associated with human immuno

142 Invasive aspergillosis (IA) by a triazole-resistant Aspe

143 Strict definition of invasive aspergillosis (IA) cases is required to allow p

144 dy, 124 DNA extracts from 14 proven/probable invasive aspergillosis (IA) cases, 2 possible IA cases,

145 The outcome of invasive aspergillosis (IA) continues to be associated w

146 Delayed diagnosis in invasive aspergillosis (IA) contributes to its high mort

147 An invasive aspergillosis (IA) disease code was most often

148 Screening of high-risk patients for invasive aspergillosis (IA) has the potential to decreas

149 methodologies for the molecular detection of invasive aspergillosis (IA) have been established by the

150 The incidence of postengraftment invasive aspergillosis (IA) in hematopoietic stem cell t

151 s DNA for the early diagnosis and therapy of invasive aspergillosis (IA) in high-risk hematological p

152 r screening is increasingly used to diagnose invasive aspergillosis (IA) in high-risk patients.

153 Invasive aspergillosis (IA) in immunocompromised hosts c

154 tus, a ubiquitous mold, is a common cause of invasive aspergillosis (IA) in immunocompromised patient

155 hoalveolar lavage (BAL) for the diagnosis of invasive aspergillosis (IA) in lung transplant recipient

156 of statin use on the risk of development of invasive aspergillosis (IA) in lung transplant recipient

157 The most common cause of invasive aspergillosis (IA) in patients with chronic gra

158 Despite suffering an outbreak of invasive aspergillosis (IA) in the intensive care unit d

159 Invasive aspergillosis (IA) is a frequent complication o

160 Invasive aspergillosis (IA) is a life-threatening compli

161 Invasive aspergillosis (IA) is a life-threatening infect

162 Invasive aspergillosis (IA) is a life-threatening system

163 Invasive aspergillosis (IA) is a rare but fatal disease

164 Invasive aspergillosis (IA) is a significant cause of mo

165 Invasive aspergillosis (IA) is an important cause of mor

166 Invasive aspergillosis (IA) is associated with poor outc

167 Invasive aspergillosis (IA) is rare among renal transpla

168 Invasive aspergillosis (IA) is the most important opport

169 A lung transplant patient with invasive aspergillosis (IA) manifested symptoms of voric

170 The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence

171 Invasive aspergillosis (IA) remains a leading cause of m

172 Invasive aspergillosis (IA) remains a leading cause of m

173 Invasive aspergillosis (IA) remains a potentially lethal

174 Diagnosis of invasive aspergillosis (IA) remains challenging.

175 Invasive aspergillosis (IA) resulting from infection by

176 y (LFA) is a rapid test for the diagnosis of invasive aspergillosis (IA) that has been almost exclusi

177 tivity of the GM LFA for proven and probable invasive aspergillosis (IA) was 100% (95% CI, 51.0 to 10

178 tool in children at high risk of developing invasive aspergillosis (IA) who are not receiving mold-a

179 nsplant recipients are at increased risk for invasive aspergillosis (IA), a disease with poor outcome

180 he most devastating infections after HSCT is invasive aspergillosis (IA), a life-threatening disease

181 8 ng/ml) of mice with experimentally induced invasive aspergillosis (IA), and levels decreased with a

182 Transplant recipients are at risk for invasive aspergillosis (IA), associated with a significa

183 onic necrotizing pulmonary aspergillosis, or invasive aspergillosis (IA), depending on the host's imm

184 ollowing four groups of patients: those with invasive aspergillosis (IA), those with other mold infec

185 ods have long been used for the diagnosis of invasive aspergillosis (IA), variable performance in cli

186 s, and A. terreus, account for most cases of invasive aspergillosis (IA), with A. nidulans, A. niger,

187 azole resistance is an increasing problem in invasive aspergillosis (IA).

188 on Usti (A. ustus) represent a rare cause of invasive aspergillosis (IA).

189 recommended as the first-line treatment for invasive aspergillosis (IA).

190 EIA) is widely utilized for the diagnosis of invasive aspergillosis (IA).

191 I) positivity threshold for the diagnosis of invasive aspergillosis (IA).

192 ression of one such ligand, KC, in mice with invasive aspergillosis improves the outcome of disease.

193 reviews the presentation and epidemiology of invasive aspergillosis in children and adolescents with

194 ergillus fumigatus, the predominant agent of invasive aspergillosis in immunocompromised hosts.

195 necessary for effective host defense against invasive aspergillosis in immunocompromised hosts.

196 leading causative agent of life-threatening invasive aspergillosis in immunocompromised individuals.

197 man fungal pathogen causing life-threatening invasive aspergillosis in immunocompromised patients.

198 tions have been used for prophylaxis against invasive aspergillosis in lung transplant recipients.

199 The outcome of invasive aspergillosis in mice treated with each agent w

200 hat the absence of CCR7 is protective during invasive aspergillosis in neutropenic mice.

201 nd CCL22, two CCR4 ligands, during pulmonary invasive aspergillosis in neutropenic mice.

202 t the Axl mAb treatment is protective during invasive aspergillosis in neutropenic mice.

203 caspofungin when used as primary therapy for invasive aspergillosis in organ transplant recipients ha

204 eutrophils and may contribute to the risk of invasive aspergillosis in patients treated with HSCT.

205 might be of great value in the clearance of invasive aspergillosis in patients with CGD.

206 ession may not be a relevant risk factor for invasive aspergillosis in the 1990s due to less frequent

207 The low pretest risk of invasive aspergillosis in the context of effective antim

208 o be the "gold standard" in the treatment of invasive aspergillosis in the immunocompromised host.

209 he immunocompetent host but can cause lethal invasive aspergillosis in the immunocompromised host.

210 ver a potential mechanism for development of invasive aspergillosis in the setting of CGD and cortico

211 ssessed the performance of any PCR assay for invasive aspergillosis in whole blood or serum and that

212 with influenza and COVID-19 with or without invasive aspergillosis in whom BAL for bacterial culture

213 Risk factors for invasive aspergillosis include prolonged and severe neut

214 The incidence of invasive aspergillosis increased from 5.7% to 11.2% duri

215 se antigens expanded in patients with active invasive aspergillosis, indicating their contribution to

216 Invasive aspergillosis induces local hemolysis in infect

217 lly bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococc

218 Invasive aspergillosis is a common and devastating pneum

219 icin B and triazoles is antagonistic against invasive aspergillosis is a controversial issue that is

220 Invasive aspergillosis is a deadly infection for which n

221 Invasive aspergillosis is a difficult-to-diagnose infect

222 Invasive aspergillosis is a leading cause of infectious

223 Invasive aspergillosis is a life-threatening complicatio

224 Invasive aspergillosis is a major threat to patients wit

225 protects immunocompromised patients against invasive aspergillosis is a novel approach to a universa

226 Invasive aspergillosis is a serious infectious complicat

227 Invasive aspergillosis is a severe pneumonia that is usu

228 Invasive aspergillosis is among the most common human fu

229 Diagnosis of invasive aspergillosis is challenging and delays in trea

230 Invasive aspergillosis is characterized by hyphal invasi

231 Invasive aspergillosis is often a consequence of immune

232 rphisms (SNPs) in PTX3 to the development of invasive aspergillosis is unknown.

233 During invasive aspergillosis, mice with a CCR7 deficiency in t

234 Invasive aspergillosis most commonly involves the sinopu

235 ics of fungal cfDNA PCR for the diagnosis of invasive aspergillosis, mucormycosis, and Pneumocystis p

236 onazole for a median of 58.0 days because of invasive aspergillosis (n = 71) or mucormycosis (n = 10)

237 that, in the lungs of neutropenic mice with invasive aspergillosis, NK cells were the major populati

238 Invasive aspergillosis occurred in 26 liver transplant r

239 roups (11.0 vs. 7.4 vs. 2.8 days, P=0.0003.) Invasive aspergillosis occurred in 44% of the lowest IgG

240 Invasive aspergillosis occurred significantly earlier af

241 ), tissue-invasive cytomegalovirus (P=0.01), invasive aspergillosis (P=0.001), total fungal infection

242 and an insignificant increase in the rate of invasive aspergillosis (P=0.20) occurred.

243 During invasive aspergillosis, platelets might be involved in i

244 The mortality and morbidity caused by invasive aspergillosis present a major obstacle to the s

245 nd caspofungin (n=40) as primary therapy for invasive aspergillosis (proven or probable) in a prospec

246 Diagnosis of invasive aspergillosis remains a significant problem.

247 and different available assays, diagnosis of invasive aspergillosis remains challenging.

248 ersistently immunosuppressed murine model of invasive aspergillosis resulted in hypovirulence, while

249 inistration of heme to mice with neutropenic invasive aspergillosis resulted in markedly increased lu

250 KC in the lung in the setting of established invasive aspergillosis results in improved host defense

251 subsets of organ transplant recipients with invasive aspergillosis, such as those with renal failure

252 on (ITT participants with proven or probable invasive aspergillosis) supported this conclusion: 31 (1

253 aluation of therapeutic strategies to combat invasive aspergillosis that closely mimic human disease

254 t we believe is a novel defense mechanism in invasive aspergillosis that is the result of alterations

255 Unlike invasive aspergillosis, the prognosis and outcome of hem

256 tigen detection for cryptococcal disease and invasive aspergillosis, the use of molecular (PCR) diagn

257 ke early therapeutic decisions when treating invasive aspergillosis using changes in biomarkers as a

258 of A. fumigatus and unique susceptibility to invasive aspergillosis via incompletely characterized me

259 r cumulative incidence of proven or probable invasive aspergillosis was 0.5% (95% CI, 0.1%-3.5%) with

260 The incidence of breakthrough invasive aspergillosis was 1.9% (5/262), all with true-p

261 The risk of invasive aspergillosis was assessed with the use of mult

262 transplant patients with proven or probable invasive aspergillosis was available from the Transplant

263 Invasive aspergillosis was documented in 5.2% (6/116) of

264 lity of galactomannan antigen for diagnosing invasive aspergillosis was evaluated in 154 liver transp

265 n's eggs and leucopenic mice, the outcome of invasive aspergillosis was similar to that described for

266 In mice with neutropenic invasive aspergillosis, we found a progressive and compa

267 To study the pathogenesis of invasive aspergillosis, we investigated the interactions

268 To investigate the role of CCR7 during invasive aspergillosis, we used a well-characterized neu

269 nsitivities and specificities for diagnosing invasive aspergillosis were 81.6% and 91.6%, and 76.9% a

270 y failure, malignant organ infiltration, and invasive aspergillosis were associated with higher hospi

271 ungal infections and invasive candidiasis or invasive aspergillosis (when possible) within 1 y posttr

272 lungs of cortisone-treated mice during early invasive aspergillosis, whereas gene expression returned

273 Among these infections is invasive aspergillosis, which is a major cause of morbid

274 and 54% were on dialysis before the onset of invasive aspergillosis, which suggest that overall sever

275 nic mice provided a protective effect during invasive aspergillosis, which was further enhanced with

276 sufficient sensitivity for the screening of invasive aspergillosis while maintaining methodological

277 ix hospitalized patients with no evidence of invasive aspergillosis who were receiving antibiotics an

278 Invasive aspergillosis, with about 5000 estimated cases

279 A. flavus is the second leading cause of invasive aspergillosis worldwide.

280 lerated and effective against IFIs including invasive aspergillosis, zygomycosis, fusariosis, and cry